CliffBio
biologic

Hyqvia

Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase

Loss of exclusivitySeptember 2026projected — 12-year biologic exclusivity estimate
CompanyTakeda Pharmaceuticals U.S.A., Inc.

Drug detail

Brand nameHyqvia
Active ingredientImmune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase
Strength0.1
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalSeptember 2014
Marketing statusRx

More from Takeda Pharmaceuticals U.S.A., Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Hyqvia patent cliff — loss of exclusivity September 2026 | CliffBio